Auritec Pharmaceuticals owns three classes of patents or exclusive licenses in the field of sustained release delivery. It has developed an innovative proprietary platform technology for sustained release of drugs given by injection (the Plexis™ platform). This platform may be used for the depot delivery of a broad range of indications, including the treatment of schizophrenia, Alzheimer’s, graft rejection, arthritis, macular edema and HIV. Auritec’s Versa™ platform utilizes the technology behind the FDA approved Vitrasert and Retisert for sustained release implants of a wide range of solubilities over the timescale of months to years. Current indications for the Versa™ technology include HIV and herpes prophylaxis.